All
Study Confirms Adding Ibrance to Endocrine Therapy May Not Improve Outcomes in Early Breast Cancer
December 8th 2021The addition of Ibrance to endocrine therapy was not associated with preventing disease recurrence in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative early breast cancer, according to final results of the phase 3 PALLAS trial.
Novel Drug Has Potential to ‘Become New Standard of Care’ in Advanced, ER-Positive Breast Cancer
December 8th 2021The use of elacestrant, an investigational therapy, elicited a 30% reduction in the risk of disease progression or death compared with standard of care in a group of patients with estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer.
Prior Successful Coping Strategies May Help Manage Cancer-Related Stress
December 6th 2021People who have successfully navigated difficult times in the past may be able to use those previous coping strategies to help them weather new stress related to a cancer diagnosis, treatment or survivorship, according to an expert from the George Washington University Cancer Center.